Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.

Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Researchers shed light on the genes that could be linked to the high mortality rates of prostate cancer among men of African ...

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease. This unexpected discovery could help doctors identify which ...

A surprising discovery reveals that a gene previously thought to accelerate esophageal cancer actually helps protect against it initially. This pivotal study could lead to better prediction and ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

The field of cancer research is beginning to embrace a broader perspective that goes beyond genetic and molecular studies, recognizing the significant role ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.